Download PDF

1. Company Snapshot

1.a. Company Description

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins.It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.


Oncternal Therapeutics, Inc.has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation.Oncternal Therapeutics, Inc.


has a research collaboration with Celularity Inc.to evaluate placental derived-cellular therapies targeting ROR1.The company is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on ONCT

Oncternal Therapeutics' recent performance was negatively driven by a wider-than-expected loss, despite topping revenue estimates. The company's Q2 loss of $2.89 per share was a significant improvement from the year-ago loss of $3 per share, but still missed analyst expectations. The company's management failed to provide a clear outlook for the future, citing the need for additional clinical trial data before making any projections. Additionally, the company's CEO and CFO did not provide any guidance on the company's pipeline or future plans, leaving investors with limited visibility into the company's prospects.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

Jul -01

Source: globenewswire.com

Card image cap

Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

Mar -07

Source: globenewswire.com

Card image cap

Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript

Aug -10

Source: seekingalpha.com

Card image cap

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates

Aug -08

Source: zacks.com

Card image cap

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Aug -08

Source: globenewswire.com

Card image cap

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

Aug -01

Source: globenewswire.com

Card image cap

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

Jul -11

Source: globenewswire.com

Card image cap

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

May -30

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.93%)

6. Segments

Novel Oncology Therapies

Expected Growth: 10.93%

Oncternal Therapeutics' novel oncology therapies drive 10.93% growth, fueled by increasing cancer prevalence, advancements in gene editing and immunotherapy, and a growing demand for targeted treatments. Strong R&D investments, strategic partnerships, and a robust pipeline of innovative products also contribute to this growth.

7. Detailed Products

Cirmtuzumab

A monoclonal antibody that targets ROR1, a receptor that is highly expressed on certain types of cancer cells, including those in mantle cell lymphoma and chronic lymphocytic leukemia.

TK216

A small molecule inhibitor of the ETS family of transcription factors, which are involved in the development and progression of certain types of cancer.

ONCT-808

A CAR-T cell therapy that targets ROR1, a receptor that is highly expressed on certain types of cancer cells.

ONCT-534

A small molecule inhibitor of the CDK2/4/6 pathway, which is involved in the regulation of cell cycle progression.

8. Oncternal Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Oncternal Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.

Bargaining Power Of Customers

Oncternal Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Oncternal Therapeutics, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size, the suppliers also have some leverage due to the specialized nature of their products.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services. Oncternal Therapeutics, Inc. needs to continuously innovate and improve its products to stay ahead of the competition.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and Oncternal Therapeutics, Inc. faces intense rivalry from established players and new entrants. The company needs to focus on differentiating its products and services to gain a competitive advantage.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.05%
Debt Cost 3.95%
Equity Weight 98.95%
Equity Cost 10.74%
WACC 10.67%
Leverage 1.06%

11. Quality Control: Oncternal Therapeutics, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Dianthus Therapeutics

A-Score: 4.6/10

Value: 6.4

Growth: 6.0

Quality: 5.0

Yield: 0.0

Momentum: 8.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Tarsus Pharmaceuticals

A-Score: 4.5/10

Value: 6.4

Growth: 3.2

Quality: 5.2

Yield: 0.0

Momentum: 9.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Champions Oncology

A-Score: 4.5/10

Value: 2.7

Growth: 7.0

Quality: 6.2

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Kymera Therapeutics

A-Score: 3.8/10

Value: 6.4

Growth: 3.1

Quality: 4.9

Yield: 0.0

Momentum: 6.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Oncternal Therapeutics

A-Score: 3.1/10

Value: 9.2

Growth: 4.3

Quality: 3.3

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
TScan Therapeutics

A-Score: 2.7/10

Value: 7.2

Growth: 4.2

Quality: 4.4

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.53$

Current Price

0.53$

Potential

-0.00%

Expected Cash-Flows